Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Item
http://www.wikidata.org/entity/Q52839837
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Aggressive FLC Escape in a Patient with IgD Myeloma.Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft modelThe prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myelomaRecent advances and future directions in targeting the secretory apparatus in multiple myeloma.Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland.Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ RatioAnalytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agentsSerum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.Non-Secretory Myeloma: Ready for a new Definition?Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens
P2860

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Item
http://www.wikidata.org/entity/Q52839837
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Serum free immunoglobulin ligh ...... erogeneity on myeloma outcome.
@en
Serum free immunoglobulin ligh ...... erogeneity on myeloma outcome.
@nl
type
label
Serum free immunoglobulin ligh ...... erogeneity on myeloma outcome.
@en
Serum free immunoglobulin ligh ...... erogeneity on myeloma outcome.
@nl
prefLabel
Serum free immunoglobulin ligh ...... erogeneity on myeloma outcome.
@en
Serum free immunoglobulin ligh ...... erogeneity on myeloma outcome.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Serum free immunoglobulin ligh ...... terogeneity on myeloma outcome
@en
P2093
P304
P31
P356
10.1182/BLOOD-2013-12-542662
P407
P433
P478
P50
P577
P698